Evidence map›Paper›PMID 29278878›Full record

ArticleCancer biomarkers : section A of Disease markers2018

Impact of etiology of chronic liver disease on hepatocellular carcinoma biomarkers.

Gabriele Ricco, Daniela Cavallone, Chiara Cosma, Gian Paolo Caviglia, Filippo Oliveri, Alessandra Biasiolo, Maria Lorena Abate, Mario Plebani, Antonina Smedile, Ferruccio Bonino and 2 more

Open access · greenAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biomarkers : section A of Disease markers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 3 pooled it
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 31 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Article
  5. [APASL clinical practice guidelines on the management of chronic hepatitis B infection: a 2026 update].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Gabriele RiccoHepatology Unit and Laboratory of Molecular Genetics and Pathology of Hepatitis Viruses, Reference Centre of the Tuscany Region for Chronic Liver Disease and Cancer, University Hospital of Pisa, 56124 Pisa, Italy.
Daniela CavalloneHepatology Unit and Laboratory of Molecular Genetics and Pathology of Hepatitis Viruses, Reference Centre of the Tuscany Region for Chronic Liver Disease and Cancer, University Hospital of Pisa, 56124 Pisa, Italy.
Chiara CosmaDepartment of Medicine, University of Padua, 35121 Padua, Italy.
Gian Paolo CavigliaDepartment of Medical Sciences, Città della Salute e della Scienza Hospital, University of Turin, 10126 Turin, Italy.
Filippo OliveriHepatology Unit and Laboratory of Molecular Genetics and Pathology of Hepatitis Viruses, Reference Centre of the Tuscany Region for Chronic Liver Disease and Cancer, University Hospital of Pisa, 56124 Pisa, Italy.
Alessandra BiasioloDepartment of Medicine, University of Padua, 35121 Padua, Italy.
Maria Lorena AbateDepartment of Medical Sciences, Città della Salute e della Scienza Hospital, University of Turin, 10126 Turin, Italy.
Mario PlebaniDepartment of Medicine, University of Padua, 35121 Padua, Italy.
Antonina SmedileDepartment of Medical Sciences, Città della Salute e della Scienza Hospital, University of Turin, 10126 Turin, Italy.
Ferruccio BoninoInstitute of Biostructure and Bioimaging, National Research Council, 80145 Naples, Italy.
Patrizia PontissoDepartment of Medicine, University of Padua, 35121 Padua, Italy.
Maurizia Rossana BrunettoHepatology Unit and Laboratory of Molecular Genetics and Pathology of Hepatitis Viruses, Reference Centre of the Tuscany Region for Chronic Liver Disease and Cancer, University Hospital of Pisa, 56124 Pisa, Italy.
University of Padua · ITAzienda Ospedaliera Universitaria Pisana · ITUniversity of Turin · ITUniversity of Pisa · ITUniversity of Siena · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe role of serum biomarkers in the surveillance of hepatocellular carcinoma (HCC) is controversial.

objectiveWe assessed the diagnostic performances of alpha-fetoprotein (AFP) and protein-induced by vitamin-K-absence/antagonist-II (PIVKA-II) in 388 cirrhotic patients with chronic liver disease (CLD).

methodsBiomarkers were quantified by automated chemiluminescent-enzyme-immunoassays (Fujirebio, Tokyo, Japan) at HCC diagnosis in 258 patients (204 males; median age 66.9 years) and in 130 cirrhotics without HCC (104 males; median-age 60.6 years). CLD etiology in HCC/non-HCC was CHB in 48/35, CHC in 126/56 and Non-Viral in 84/39.

resultsOverall AUROC values for AFP and PIVKA-II were 0.698 (95%CI = 0.642-0.753, P< 0.001) and 0.780 (95%CI = 0.730-0.831, P< 0.001). AFP/PIVKA-II AUROC (95%CI) were: 0.822 (0.728-0.915)/0.833 (0.739-0.926) in CHB, 0.648 (0.560-0.736)/0.732 (0.650-0.814) in CHC; 0.640 (0.540-0.740)/0.806 (0.722-0.889) in Non-Viral-CLD. AFP/PIVKA-II diagnostic accuracy was 40.5-59.8%/62.7-73.5% and combining both markers 78.2% for CHB, 77% for Non-Viral-CLD and 75% for CHC. AFP correlated with ALT in HCC patients with CHC (ρ= 0.463/P< 0.001) and Non-Viral CLD (ρ= 0.359/P= 0.047), but not in CHB (treated with antivirals). PIVKA-II correlated with tumour size independently of CLD-etiology (P< 0.001) and AFP in CHB patients only (P= 0.007).

conclusionThe diagnostic performance of AFP and PIVKA-II is significantly influenced by the etiology and activity of CLD; their combination provides a better diagnostic accuracy.

Indexed as

Biomarkers, TumorAdultAgedAged, 80 and overalpha-FetoproteinsBiomarkersCarcinoma, HepatocellularChronic DiseaseFemaleHumansImmunoenzyme TechniquesItalyLiver DiseasesLiver NeoplasmsMaleMiddle Agedacarboxyprothrombinalpha-FetoproteinsBiomarkersBiomarkers, TumorProtein PrecursorsProthrombinAlpha-fetoproteinchronic liver diseaseHCCprotein induced by vitamin K absence/antagonist-II

Identifiers

PMID29278878
PMCPMC13078307
OpenAlexW2779019218

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.